Antitumor activity of five new platinum complexes having a glycolate leaving ligand.
10.3346/jkms.1995.10.4.269
- Author:
Weon Seon HONG
1
;
Young Il MIN
;
Hun Taek KIM
;
Yong Baik CHO
;
Key H KIM
;
Dae Kee KIM
Author Information
1. Department of Internal Medicine, University of Ulsan, Seoul, Korea.
- Publication Type:Original Article ; Comparative Study
- Keywords:
Platinum complexes;
Glycolate;
Antitumor activity;
Lung;
Stomach;
Cancer cell line
- MeSH:
Antineoplastic Agents/*pharmacology;
Cisplatin/pharmacology;
Comparative Study;
Drug Evaluation, Preclinical;
Human;
Organoplatinum Compounds/*pharmacology;
Tumor Cells, Cultured
- From:Journal of Korean Medical Science
1995;10(4):269-274
- CountryRepublic of Korea
- Language:English
-
Abstract:
In an attempt to develop a new anticancer platinum complex with greater or equivalent antitumor activity but reduced side effects compared with cisplatin (CDDP), a series of new platinum complexes having a glycolate leaving ligand was synthesized. Among them, five complexes were selected for further development on the basis of adequate water solubility, low nephrotoxicity and high antitumor activity in a murine system. The chemosensitivity of these five complexes was examined in MTT assay against two human pulmonary adenocarcinoma cell lines, PC-9 and PC-14, and two human stomach adenocarcinoma cell lines, MKN-45 and KATO III. Their IC50 and relative antitumor activity (RAA) values were compared with those of CDDP and 254-S, a second-generation platinum complex with a glycolate leaving ligand under phase III clinical trial. The lowest mean IC50 value was observed in CDDP, followed by SKI 2034R and SKI 2033R. In this study, the antitumor activity was evaluated in terms of RAA values and SKI 2034R showed the highest RAA value. The order of RAA values was SKI 2034R > CDDP > SKI 2032R > SKI 2033R > SKI 2030R > SKI 2029R > 254-S. Based on the RAA order, we have recommended SKI 2034R as the most promising candidate for further development of a clinically useful platinum complex.
